Lymphoma Hub | Quarter One 2020 Update

The Lymphoma Hub kicked off 2020 with the launch of its brand-new website. The hub has been redesigned to facilitate navigation, allowing users to filter by disease subtypes, therapeutics, congresses, trials, and expert opinions. The updated platform further enables the Lymphoma Hub to deliver the latest clinical developments from the lymphoma community. Ultimately, the Lymphoma Hub strives to inform real-world clinical practice by providing the latest trial and drug updates, key literature, and congress coverage.

So far, the Lymphoma Hub has covered two educational themes with the aim to expand the information available on key topics in lymphoma: Improving front-line treatment in chronic lymphocytic leukemia (CLL) was the focus over January and February before proceeding to investigate the value of positron emission technology (PET) as a prognostic tool in lymphoma.

In February 2020, the Lymphoma Hub was pleased to provide live coverage from the 2nd European CAR T Cell Meeting, Sitges, ES, where it held expert interviews on the latest in chimeric antigen receptor (CAR) T-cell therapy. The Lymphoma Hub provided a comprehensive summary of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE) practical clinical recommendations on the management of patients undergoing CAR T-cell therapy; a substantial landmark in the field. In addition to providing coverage of the congress, the Lymphoma Hub was recognized as one of the top influencers on Twitter at the event. This accomplishment indicates the widespread reach and impact of the Lymphoma Hub content.

The Lymphoma Hub, founded in partnership with the European Lymphoma Institute (ELI) and brought to you by Scientific Education Support (SES), is dedicated to providing up-to-date, unbiased material for healthcare professionals. The Lymphoma Hub owes thanks to both existing and new sponsors, without whom the platform would not be possible. Last quarter, the Lymphoma Hub welcomed Novartis (Silver) and Epizyme (Contributor) as supporters and would like to extend a special thanks to their support going forward. The Lymphoma Hub remains forever grateful to our ongoing supporters – Celgene (Platinum), AstraZeneca (Silver), Gilead (Silver), Janssen Oncology (Silver), Nordic Nanovector (Bronze), Roche (Bronze) and Karyopharm Therapeutics (Contributor).

For more information on the Lymphoma Hub, please visit www.lymphomahub.com. For media enquiries, or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.